Biotechnology companies in Washington focus on developing advanced medical treatments, therapeutics, and diagnostics through biological processes. This industry hosts firms that specialize in everything from pharmaceuticals to genetic engineering, harnessing nature to tackle pressing health challenges. As innovations in fields like genome editing and synthetic biology progress, Washington's biotechnology sector is poised for significant growth. Collaborations with local universities and research institutions strengthen this ecosystem, helping to bring groundbreaking solutions to market more efficiently. Ultimately, these companies aim to improve patient care and respond to global health crises with their cutting-edge technologies.

The companies listed here range in size from small startups to large entities, most operating from Seattle or Bothell, Washington. Founded between 1996 and 2024, they span areas including cancer therapeutics, immunotherapies, and diagnostic solutions. With some companies being venture capital-backed, their innovative approaches tackle critical health issues using advanced research and diverse methodologies. This mix of established organizations and newer entrants reflects Washington's vibrant biotechnology scene, driven by talented professionals actively seeking solutions for unmet medical needs.

Continue reading to explore Washington's top biotechnology companies.

Top 25 Biotechnology Companies in Washington

1. Seattle Genetics

• Website: seattlegenetics.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: seattle-genetics

Seattle Genetics, founded in 1998 and based in Bothell, Washington, is a biopharmaceutical company that focuses on developing innovative therapies for cancer treatment. The company is particularly known for its pioneering work in antibody-drug conjugates (ADCs), which combine targeted antibodies with potent cytotoxic drugs to deliver treatment directly to cancer cells. This approach aims to minimize damage to healthy cells while maximizing therapeutic effects. Seattle Genetics has a robust pipeline of products and is actively involved in clinical trials to bring new therapies to market. Their commitment to research and development is evident in their collaborations with various partners and their focus on addressing unmet medical needs in oncology. With a workforce of over 2,000 employees, Seattle Genetics continues to play a vital role in the biotechnology industry, striving to improve patient outcomes through innovative science.

2. AGC Biologics

• Website: agcbio.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Employee distribution: Denmark 47%, United States (USA) 35%, Italy 12%, Other 6%
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: agcbiologics

AGC Biologics, founded in 2001 and based in Bothell, Washington, is a private contract development and manufacturing organization (CDMO) that specializes in biologics and advanced therapies. The company offers a wide range of services tailored to the needs of biopharmaceutical companies, including mammalian and microbial production, cell therapy, and fill & finish services. With a workforce of over 2,500 employees, AGC Biologics operates globally, with facilities in the United States, Denmark, Italy, Germany, and Japan. Their mission is to collaborate closely with clients to expedite the development and manufacturing of new biopharmaceuticals, ultimately improving patient outcomes. AGC Biologics has developed specialized platforms and programs, such as AGCellerate™ and BravoAAV™, to streamline processes and enhance efficiency in bringing therapies to market. The company has not reported any recent funding, indicating a stable operational model that relies on its established client base and service offerings.

3. Lumen Bioscience

• Website: lumen.bio
• Ownership type: Private Equity
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $16.2M, October 2023
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: lumen-bioscience

Lumen Bioscience, based in Seattle, Washington, is a biopharmaceutical company that specializes in the development and manufacturing of biologic drugs aimed at treating diseases with significant unmet medical needs. Founded in 2017, Lumen has developed a patented technology platform that accelerates drug development while reducing costs and risks compared to traditional methods. The company collaborates with pharmaceutical firms to create solutions for health issues that have been largely overlooked, such as C. difficile infections, COVID-19 gastrointestinal symptoms, and inflammatory bowel disease. Lumen's pipeline includes several promising candidates, and their recent funding of $16.2 million in October 2023 underscores their active role in the biotechnology industry and their potential to make a meaningful impact on public health.

4. Outpace Bio

• Website: outpacebio.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $144.0M, August 2024
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: outpace-bio

Outpace Bio, Inc. is a biotechnology firm based in Seattle, Washington, founded in 2020. The company specializes in the design and engineering of therapeutic proteins, leveraging artificial intelligence to streamline and enhance drug development processes. Outpace Bio primarily serves biopharma companies and academic institutions, providing innovative solutions aimed at creating effective therapies. The company has gained attention for its use of advanced AI tools, such as RF Diffusion, which generates new protein designs, and ProteinMPNN, which helps fill in amino acid sequences. In August 2024, Outpace Bio secured $144 million in Series B funding, reflecting strong investor interest in their technology and potential. Their collaborative efforts with other biotech firms and academic institutions further underscore their commitment to advancing the field of protein design and therapeutic development.

5. Talus Bio

• Website: talus.bio
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $11.2M, August 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: talus-bio

Talus Bio, founded in 2020 and based in Seattle, Washington, is a biotechnology company dedicated to drug discovery and development. The firm specializes in creating therapeutics that target transcription factors, proteins that play a vital role in regulating gene expression and are implicated in various diseases, including cancer and diabetes. Their proprietary platform, known as MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors), integrates advanced technologies such as functional proteomics, automated biology, and machine learning to identify and optimize drug candidates. Talus Bio collaborates with pharmaceutical companies and research institutions to tackle significant unmet medical needs. Recently, they secured $11.2 million in funding to further enhance their AI-driven platform, which aims to revolutionize the discovery of drugs for previously undruggable targets. With a team of experts in proteomics, biochemistry, and computational biology, Talus Bio is positioned to make meaningful contributions to the field of biotechnology.

6. Shape Therapeutics Inc.

• Website: shapetx.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $112.0M, July 2021
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: shapetx

Shape Therapeutics Inc., based in Seattle, Washington, is a biotechnology firm that specializes in programmable RNA medicines. Founded in 2018, the company aims to repair genetic causes of diseases by leveraging artificial intelligence and RNA technology. Their innovative platform allows for the design and development of RNA-based therapies that can address a wide range of genetic disorders. Shape Therapeutics has attracted significant investment, securing $112 million in a Series B funding round in July 2021, which underscores the confidence investors have in their approach and technology. The company operates with a focus on research, development, and manufacturing, catering to healthcare providers and researchers seeking advanced therapeutic solutions. Their proprietary RNAfix® platform is designed to correct mutations and modulate gene expression, showcasing their commitment to creating effective and accessible medicines.

7. Cyrus Biotechnology

• Website: cyrusbio.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, February 2024
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: cyrus-biotechnology

Cyrus Biotechnology, founded in 2014 and based in Seattle, Washington, specializes in molecular modeling and design. The company is dedicated to developing innovative therapeutics aimed at treating autoimmune diseases, infectious diseases, and oncology. Utilizing an AI-driven discovery platform, Cyrus Bio focuses on naturally occurring proteins, transforming them into advanced therapeutics through deep mutagenesis and sophisticated laboratory methods. Their pipeline includes promising candidates such as IdeS for autoimmune diseases and a COVID-19 therapeutic candidate that targets all variants of the virus. Cyrus has collaborated with over 30 partner firms, including notable names like Janssen and Genentech, showcasing its active role in the biotechnology field. The company is backed by top-tier venture capital investors, further solidifying its position in the industry.

8. Arbele

• Website: arbelebio.com
• Ownership type: Private
• Headquarters: Bellevue, Washington, United States (USA)
• Employee distribution: Hong Kong S.A.R 76%, United States (USA) 12%, Singapore 12%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: arbele

Arbele is a biotechnology firm based in Bellevue, Washington, founded in 2016. The company specializes in developing innovative treatments for gastrointestinal cancers, focusing on immunotherapy and advanced diagnostics. Their proprietary technology platform includes TriAx Multispecific biologics and AI-CAR technology, aimed at treating cancers such as stomach, pancreas, colon, bile duct, and liver. Arbele's primary target is Cadherin-17 (CDH17), a biomarker associated with various gastrointestinal cancers. The company operates in a clinical stage, indicating active development of their therapies. With a small team of around 17 employees, Arbele is strategically positioned to address significant gaps in cancer treatment, catering to healthcare providers and patients seeking effective solutions. Their commitment to scientific advancement and patient care underscores their role in the biotechnology industry.

9. Bonum Therapeutics

• Website: bonumtx.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $93.0M, November 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: bonum-therapeutics

Bonum Therapeutics, founded in 2021 and based in Seattle, Washington, is a biotechnology firm dedicated to the development of innovative therapeutics aimed at treating cancer and other diseases. The company specializes in context-dependent cytokine-based drugs, which are designed to enhance the immune response while reducing systemic toxicity. Their research and development model leverages expertise in drug discovery and protein engineering, focusing on creating therapies that are only active when bound to specific targets. This approach aims to improve treatment efficacy and safety, addressing significant challenges in current cancer therapies. Bonum's technology platform has broad potential applications, including in autoimmune diseases and metabolic disorders. The company has gained traction in the industry, evidenced by its successful Series A funding round of $93 million in November 2022, which underscores the confidence investors have in its innovative approach and future prospects.

10. InduPro

• Website: induprotx.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $85.0M, June 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: induprolabs

InduPro is a biotechnology company based in Seattle, Washington, founded in 2022. The company specializes in the development of innovative protein therapeutics, focusing on proximity-based drug discovery to create targeted therapies for cancer and autoimmune diseases. InduPro employs advanced scientific platforms to manipulate protein interactions on cell surfaces, aiming to unlock new therapeutic pathways. Their proprietary technologies, such as the Membrane Interactomics (MInt) database and the ARRIS platform, allow for the identification of novel therapeutic targets and the engineering of next-generation therapeutics. In June 2024, InduPro raised $85 million in Series A funding, co-led by prominent venture capital firms, which underscores their potential in the biotechnology field. The company is actively working on a pipeline of therapies that address significant medical needs, particularly in oncology and immunology.

11. Cajal Neuroscience

• Website: cajalneuro.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $96.0M, November 2022
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: cajal-neuroscience

Cajal Neuroscience Inc. is a biotechnology firm based in Seattle, Washington, established in 2020. The company specializes in drug discovery aimed at treating neurodegenerative diseases, including Alzheimer's and Parkinson's. Cajal employs cutting-edge scientific techniques to develop therapeutics that can alter the progression of these debilitating conditions. Their innovative approach integrates high-throughput microscopy, functional genomics, and multi-omics analyses to identify and validate new drug targets. Cajal's clientele includes healthcare providers and pharmaceutical companies seeking novel treatment solutions. In November 2022, the company raised $96 million in a Series A funding round, underscoring its potential and the confidence investors have in its mission to transform the landscape of neurodegenerative disease treatment.

12. OncoResponse Inc.

• Website: oncoresponseinc.com
• Ownership type: Private
• Headquarters: Seattle, Washington, United States (USA)
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: oncoresponse-inc.

OncoResponse Inc. is a biotechnology firm based in Seattle, Washington, founded in 2016. The company specializes in the development of therapeutic antibodies aimed at treating cancer. Their innovative approach is centered on understanding and utilizing the immune responses of 'Elite Cancer Responders'—patients who have achieved remarkable outcomes with existing cancer therapies. This strategy allows OncoResponse to create novel immunotherapies that target the tumor microenvironment, aiming to convert 'cold' tumors into 'hot' ones, thereby enhancing the effectiveness of immunotherapy. The company collaborates with MD Anderson Cancer Center, which not only strengthens their research capabilities but also underscores their commitment to advancing cancer treatment. OncoResponse's pipeline includes several promising monoclonal antibodies that are currently in preclinical studies, focusing on reversing immunosuppression in the tumor microenvironment and boosting immune cell activity.

13. Viome Life Sciences

• Website: viomelifesciences.com
• Ownership type: Venture Capital
• Headquarters: Bellevue, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2022
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: viome-research-institute

Viome Life Sciences, founded in 2016 and based in Bellevue, Washington, is a health technology company dedicated to chronic disease prevention and treatment. The company specializes in analyzing gene expression and the human microbiome to provide personalized health insights and precision nutrition recommendations. Viome's services are designed for individuals seeking to enhance their health by understanding their biological makeup. They employ advanced technologies, including metatranscriptomics and machine learning, to identify patterns that can lead to better health outcomes. Viome has accumulated a substantial dataset from over 300,000 samples, which supports their research initiatives and clinical studies. Their work has garnered attention for its potential to revolutionize how chronic diseases and cancer are diagnosed and treated, making them a notable player in the biotechnology field.

14. Immusoft

• Website: immusoft.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $8.0M, January 2023
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: immusoft-corporation

Immusoft, based in Seattle, Washington, is a biotechnology company founded in 2009. The firm specializes in the development of engineered B cells for therapeutic protein delivery, focusing on innovative treatments for rare diseases. Immusoft utilizes its proprietary Immune System Programming (ISP) technology, which involves collecting a patient's B cells and programming them to act as biofactories that produce therapeutic proteins. This approach aims to enhance patient outcomes by providing personalized therapies tailored to individual needs. The company has recently secured $8 million in funding as of January 2023, indicating ongoing support for its research and development efforts. Immusoft is actively involved in clinical trials, with its ISP-001 therapy showing promising results for Mucopolysaccharidosis Type I, further solidifying its position in the biotechnology field.

15. Accelerator Life Science Partners

• Website: acceleratorlsp.com
• Ownership type: Private
• Headquarters: Seattle, Washington, United States (USA)
• Founded year: 2003
• Headcount: 1-10
• LinkedIn: accelerator-alumni

Accelerator Life Science Partners is a biotechnology investment firm based in Seattle, Washington, founded in 2003. The firm specializes in building successful biotechnology companies by leveraging innovative scientific discoveries. They provide a comprehensive toolkit that includes business, scientific, and financial resources to early-stage biotech companies. Accelerator partners with entrepreneurs to help transform novel technologies into market-ready products that can significantly impact global health. Their portfolio includes companies like Rodeo Therapeutics, which was acquired by Amgen for up to $721 million, and ApoGen, which focuses on addressing drug resistance in cancer therapy. Accelerator's model emphasizes collaboration and strategic support, making them a vital contributor to the biotechnology ecosystem.

16. InduPro

• Website: induprolabs.com
• Ownership type: Private
• Headquarters: Seattle, Washington, United States (USA)
• Founded year: 2022
• Headcount: 1-10
• LinkedIn: induprolabs

InduPro is a biotechnology firm based in Seattle, Washington, founded in 2022. The company specializes in developing innovative drug therapies aimed at treating oncology and autoimmune diseases. InduPro employs proprietary platforms to create proximity-based therapeutics, which focus on the spatial relationships of proteins on cell surfaces. This approach allows them to manipulate protein interactions, potentially leading to new treatment options for patients with significant medical needs. InduPro has attracted attention in the industry, having raised $85 million in Series A financing, co-led by notable investors. Their pipeline includes programs targeting tumor-associated proximity antigens and immuno-oncology, showcasing their commitment to advancing therapeutic possibilities. With a team of experienced scientists from pharmaceutical backgrounds, InduPro is positioned to make a meaningful impact in the biotechnology sector.

17. Deverra Therapeutics

• Website: deverratx.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $3.5M, September 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: deverra-therapeutics

Deverra Therapeutics, Inc. is a clinical stage biotechnology company based in Seattle, Washington. Founded in 2020, the company specializes in developing allogeneic, off-the-shelf cellular immunotherapies aimed at treating cancer and infectious diseases. Their mission is to create accessible therapies that do not require donor-patient matching, utilizing healthy donor umbilical cord blood cells. Deverra's lead product, Dilanubicel, has been evaluated in clinical trials and has demonstrated a statistically significant increase in remission rates for patients with newly diagnosed acute myeloid leukemia (AML). The company has also developed natural killer (NK) cell therapies and is exploring engineered immune effector cells for various cancer treatments. Recently, Deverra secured $3.5 million in funding, which reflects investor confidence in their innovative approach and potential impact on patient care.

18. Universal Cells

• Website: universalcells.com
• Ownership type: Corporate
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Latest funding: February 2018
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: universal-cells

Universal Cells, based in Seattle, Washington, is a biotechnology firm founded in 2013. The company focuses on engineered stem cell therapies, specifically developing universal donor stem cells that can be utilized in clinical applications without the risk of immune rejection. Their innovative approach involves editing genes responsible for immune recognition, allowing for the creation of pluripotent stem cells that can differentiate into various therapeutic cell types. Universal Cells collaborates with healthcare providers and research institutions, aiming to provide solutions in cell therapy. The company is a wholly owned subsidiary of Astellas Pharma, which offers substantial resources for product development and clinical trials. Universal Cells is committed to advancing their stem cell products through partnerships and collaborations, contributing to the transformation of modern medicine.

19. Variant Bio

• Website: variantbio.com
• Ownership type: Private Equity
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $105.0M, November 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: variantbio

Variant Bio, founded in 2018 and based in Seattle, Washington, is a biotechnology company dedicated to genomic drug discovery and development. The company aims to harness the power of human genetic diversity to create life-saving therapies. Their operations are characterized by a strong emphasis on ethical research practices and community engagement, ensuring that the populations they work with are respected and benefit from the research conducted. Variant Bio collaborates with healthcare professionals and research institutions to address unmet medical needs through innovative genetic insights. They have developed a proprietary platform, VB-Inference, which integrates multi-omic data to identify therapeutic targets with strong genetic evidence. The company has successfully raised $105 million in funding, reflecting its potential and the interest of investors in its mission and capabilities.

20. InBios International

• Website: inbios.com
• Ownership type: Private
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 71%, Puerto Rico 14%, Czech Republic 14%
• Latest funding: $100,000, November 2022
• Founded year: 1996
• Headcount: 51-200
• LinkedIn: alza-corporation

InBios International, Inc. is a biotechnology company based in Seattle, Washington, founded in 1996. The company specializes in the design, development, and manufacture of diagnostic tests aimed at infectious diseases. InBios offers a variety of products, including ELISA kits and rapid immunoassays, which are essential tools for healthcare providers and laboratories in diagnosing and managing infectious diseases. Their product portfolio includes tests for diseases such as COVID-19, Zika, dengue, and various other viral and parasitic infections. InBios operates under strict quality standards, being FDA registered, USDA licensed, and ISO 13485:2016 certified. The company has a strong commitment to improving health outcomes globally, and their recent FDA clearances for COVID-19 testing products highlight their active role in addressing urgent public health needs. InBios also provides contract manufacturing and assay development services, further solidifying their position in the biotechnology industry.

21. HDT Bio

• Website: hdt.bio
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, October 2023
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: onc-bio

HDT Bio is a Seattle-based clinical-stage biopharmaceutical company founded in 2018. The company specializes in the development of advanced RNA vaccine products aimed at treating and preventing infectious diseases and cancers. Utilizing its proprietary LION™ technology, HDT Bio enhances the safety, potency, and manufacturing processes of its vaccines. The company is actively involved in clinical trials, including a COVID-19 vaccine currently in Phase 1 trials in the U.S. HDT Bio has received significant funding, including a recent $1 million grant in 2023, to support its innovative projects. The company collaborates with various healthcare providers and research institutions, emphasizing its commitment to improving public health and addressing global health equity. Their pipeline includes vaccines targeting diseases such as shingles, HIV, and various cancers, showcasing their ambition to make a meaningful impact in the biopharmaceutical industry.

22. Oisin Biotechnologies

• Website: oisinbio.com
• Ownership type: Corporate
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $15.0M, July 2024
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: oisin-biotechnologies

Oisin Biotechnologies, founded in 2014 and based in Seattle, Washington, is a biotechnology firm dedicated to advancing genetic medicines that target health and longevity. The company specializes in therapies designed to combat age-related conditions, focusing on innovative solutions that stimulate muscle growth, selectively eliminate fat cells, and remove senescent cells. Their proprietary delivery technology, known as Fusogenix™ Proteo-Lipid Vehicle (PLV), allows for effective distribution of DNA and RNA payloads, enhancing the potential for safe and repeated dosing. With a small team of around 17 employees, Oisin has made strides in the biotechnology sector, recently securing $15 million in Series A funding in July 2024, which underscores their growth potential and commitment to addressing the challenges of aging. Their work appeals to both individuals and organizations seeking effective interventions for frailty and other health issues associated with aging.

23. Arzeda

• Website: arzeda.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $38.0M, September 2024
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: arzeda-corp

Arzeda is a biotechnology company based in Seattle, Washington, founded in 2009. The company specializes in protein design and enzyme development, utilizing its proprietary Intelligent Protein Design Technology™. This technology merges computational design with artificial intelligence to create novel proteins and enzymes tailored for various industries, including food, personal care, and materials science. Arzeda collaborates with major brands, such as Unilever and W. L. Gore & Associates, to enhance product sustainability and performance. Their work includes developing enzymes that improve cleaning products and creating sustainable plant-based oils. Recently, Arzeda secured $38 million in a Series C funding round, underscoring their growth and the confidence investors have in their innovative solutions. With a team of scientists and engineers, Arzeda is committed to addressing some of the toughest challenges in biotechnology, making a notable impact across multiple sectors.

24. Pluristyx, Inc.

• Website: pluristyx.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: pluristyx

Pluristyx, Inc., founded in 2018 and based in Seattle, Washington, is a biotechnology company that specializes in stem cell therapies and related technologies. The company offers a range of products and services, including induced pluripotent stem cells (iPSCs), gene editing, and GMP manufacturing. Their clientele primarily consists of biotechnology and pharmaceutical companies that require advanced solutions for research and development. Pluristyx operates with a mission to accelerate the development of cellular therapies, providing end-to-end support throughout the product lifecycle. Their proprietary panCELLa Platform facilitates the development of iPSC-based therapies, streamlining processes from concept to clinical application. The company has also announced partnerships and collaborations, such as a recent license agreement with Humacyte to develop bioengineered solutions, showcasing their active involvement in the biotechnology sector.

25. A-Alpha Bio

• Website: aalphabio.com
• Ownership type: Venture Capital
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 97%, Israel 3%
• Latest funding: Other (Grant), $14.5M, May 2024
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: aalphabio

A-Alpha Bio, founded in 2017 and based in Seattle, Washington, is a biotechnology firm specializing in the measurement, prediction, and engineering of protein-protein interactions. The company leverages synthetic biology and machine learning to provide high-resolution data that accelerates therapeutic discovery. Their platforms, AlphaSeq and AlphaBind, are designed to facilitate antibody discovery and enhance the drug development process. A-Alpha Bio collaborates with pharmaceutical companies and research institutions, aiming to address unmet medical needs through innovative solutions. The company has received significant funding, including a recent grant of $14.5 million in May 2024, which underscores its commitment to advancing its technology and therapeutic pipeline. A-Alpha Bio's focus on protein interactions positions it as a key player in the biotechnology industry, particularly in the fields of immunotherapy and molecular glue discovery.

Biotechnology Insights: Key Companies in Washington

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!